-DOCSTART- -X- O
New -X- _ O
treatments -X- _ O
and -X- _ O
new -X- _ O
drugs -X- _ O
for -X- _ O
avian -X- _ B-Patient
influenza -X- _ I-Patient
virus -X- _ I-Patient
( -X- _ I-Patient
AIV -X- _ I-Patient
) -X- _ I-Patient
infection -X- _ O
are -X- _ O
developed -X- _ O
continually -X- _ O
, -X- _ O
but -X- _ O
there -X- _ O
are -X- _ O
still -X- _ O
high -X- _ O
mortality -X- _ O
rates. -X- _ O
The -X- _ O
main -X- _ O
reason -X- _ O
may -X- _ O
be -X- _ O
that -X- _ O
not -X- _ O
all -X- _ O
cell -X- _ O
death -X- _ O
pathways -X- _ O
induced -X- _ O
by -X- _ O
AIV -X- _ B-Patient
were -X- _ O
blocked -X- _ O
by -X- _ O
the -X- _ O
current -X- _ O
therapies. -X- _ O
In -X- _ O
this -X- _ O
review -X- _ O
, -X- _ O
drugs -X- _ B-Intervention
for -X- _ I-Intervention
AIV -X- _ I-Intervention
and -X- _ O
associated -X- _ O
acute -X- _ O
respiratory -X- _ O
distress -X- _ O
syndrome -X- _ O
( -X- _ O
ARDS -X- _ O
) -X- _ O
are -X- _ O
summarized. -X- _ O
The -X- _ O
roles -X- _ B-Intervention
of -X- _ I-Intervention
antioxidant -X- _ I-Intervention
( -X- _ I-Intervention
vitamin -X- _ I-Intervention
C -X- _ I-Intervention
) -X- _ I-Intervention
and -X- _ I-Intervention
multiple -X- _ I-Intervention
immunomodulators -X- _ I-Intervention
( -X- _ I-Intervention
such -X- _ I-Intervention
as -X- _ I-Intervention
Celecoxib -X- _ I-Intervention
, -X- _ I-Intervention
Mesalazine -X- _ I-Intervention
and -X- _ I-Intervention
Eritoran -X- _ I-Intervention
) -X- _ I-Intervention
are -X- _ O
discussed. -X- _ O
The -X- _ O
clinical -X- _ O
care -X- _ O
of -X- _ O
ARDS -X- _ O
may -X- _ O
result -X- _ O
in -X- _ O
ischemia -X- _ O
reperfusion -X- _ O
injury -X- _ O
to -X- _ O
poorly -X- _ O
ventilated -X- _ O
alveolar -X- _ O
cells. -X- _ O
Cyclosporin -X- _ B-Intervention
A -X- _ I-Intervention
should -X- _ O
effectively -X- _ O
inhibit -X- _ O
this -X- _ O
kind -X- _ O
of -X- _ O
damages -X- _ O
and -X- _ O
, -X- _ O
therefore -X- _ O
, -X- _ O
may -X- _ O
be -X- _ O
the -X- _ O
key -X- _ O
drug -X- _ O
for -X- _ O
the -X- _ O
survival -X- _ O
of -X- _ O
patients -X- _ O
with -X- _ O
virus-induced -X- _ O
ARDS. -X- _ O
Treatment -X- _ O
with -X- _ O
protease -X- _ B-Intervention
inhibitor -X- _ I-Intervention
Ulinastatin -X- _ I-Intervention
could -X- _ O
also -X- _ O
protect -X- _ O
lysosome -X- _ O
integrity -X- _ O
after -X- _ O
the -X- _ O
infection. -X- _ O
Through -X- _ O
these -X- _ O
analyses -X- _ O
, -X- _ O
a -X- _ O
large -X- _ B-Outcome
drug -X- _ I-Outcome
combination -X- _ I-Outcome
is -X- _ I-Outcome
proposed -X- _ I-Outcome
, -X- _ I-Outcome
which -X- _ I-Outcome
may -X- _ I-Outcome
hypothetically -X- _ I-Outcome
greatly -X- _ I-Outcome
reduce -X- _ I-Outcome
the -X- _ I-Outcome
mortality -X- _ I-Outcome
rate -X- _ I-Outcome
. -X- _ O

